Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
pharmaphorum3d
ASH: CRISPR, Vertex' CTX001 hits the mark in red cell disorders
It uses CRISPR/Cas9 to make a patient’s haematopoietic stem cells produce high levels of foetal haemoglobin (HbF) in red blood cells, by introducing a gene known as BCL11A which down-regulates ...
precisionmedicineonline2d
Precision Medicine Supporters Worry About NIH Indirect Rate Cut's Impact on Advances, Workforce
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...
eLife5d
Sphingosine-1-phosphate signaling regulates the ability of Müller glia to become neurogenic, proliferating progenitor-like cells
This important study investigates the signaling pathways regulating retinal regeneration. Convincing evidence shows that the sphingosine-1-phosphate (S1P) signaling pathway is inhibited following ...